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M. HAEMOLYTICA OUTER MEMBRANE 
PROTEIN PlPE AS A VACCINE OR VACCINE 
COMPONENT AGAINST SHIPPING FEVER 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application is a divisional of U.S. patent application 
Ser. No. 10/696,544, filed Oct. 29, 2003, now abandoned, 
which application claims the benefit of U.S. Provisional 
Patent Application Ser. No. 60/422,305, filed Oct. 30, 2002, 
both of which applications are incorporated herein by ref-
erence. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention was supported in part by the U.S. Gov-
ermnent. The U.S. Govermnent has certain rights in the 
invention as provided for by the terms of Grant Nos. 
95-37204-1999 and/or 2002-02232 awarded by USDA-CS-
REES under the National Research Initiative Competitive 
Grants Program. 
BACKGROUND OF THE INVENTION 
1. Technical Field 
The present invention relates generally to the prevention 
of bovine respiratory disease (BRD) and, in particular, its 
most severe form, termed "shipping fever". More specifi-
cally, the present invention relates to the use of M. 
haemolytica outer membrane protein PlpE and subunits 
thereof as a vaccine or vaccine component against shipping 
fever. 
2. Background 
BRD is the major cause of beef cattle morbidity and 
mortality and of economic losses to the beef cattle industry. 
The cost of BRD to beef cattle producers approaches $1 
billion annually. 
BRD arises from the interaction of numerous contributing 
factors including physical stresses associated with weaning, 
shipment, inclement weather, and overcrowding coupled 
with viral and bacterial infections. The end result in severe 
cases is colonization of the lungs with pathogenic bacteria 
resulting in severe pneumonia. Pasteurella multocida, Hae-
mophilus somnus and Mannheimia (formerly Pasteurella) 
haemolytica are associated with bovine pneumonia. How-
ever, Mannheimia haemolytica serotype 1 (Sl) is by far the 
most important and commonly isolated bacterial pathogen in 
development of the often-fatal fibrinous pleuropneumonia in 
beef cattle known as pneumonic pasteurellosis or shipping 
fever. 
Prevention and control of shipping fever in feedlots is 
attempted through three means: antibiotic treatment upon 
arrival of cattle at the feedlot, antibiotic therapy for sick 
cattle, and vaccination against BRD viruses and M. 
haemolytica. The extensive use of antibiotics to control 
shipping fever increases the possibility of antibiotic residues 
in meat and the development of drug-resistant bacteria in 
cattle, including those bacteria with potential impact on 
human health such as Salmonella and E. coli O157:H7. 
Viral and bacterial vaccines for the control of shipping 
fever have been used for many years. Despite their avail-
ability, the disease continues to be a major bovine health 
problem. Because of the economic constraints of the cattle 
industry, bovine vaccines must be low in cost. Therefore, 
current M. haemolytica vaccines are crude, usually consist-
2 
ing of a culture supernatant, which contains M. haemolytica 
leukotoxin and sloughed surface proteins, and/or the killed 
bacterium. Perino and Hunsaker reviewed published field 
studies on commercial M. haemolytica vaccines and found 
5 that efficacy could be established in only 50% of the trials. 
(Bov Practitioner 1997; 31: 59-66) Thus, there is a continu-
ing need that M. haemolytica vaccines be improved. 
Immunity against M. haemolytica is thought to be prima-
rily through production of serum antibodies that neutralize 
10 the secreted leukotoxin (LKT) and antibodies against sur-
face antigens. The specific surface antigens that are impor-
tant in stimulating host immunity to M. haemolytica are not 
known; however, several studies point towards the impor-
tance of outer membrane proteins (OMPs). Pandher et al. 
15 demonstrated 21 surface-exposed immunogenic outer mem-
brane proteins in M. haemolytica Sl using protease treat-
ment and Western blotting. (Pandher K, Murphy G L, Confer 
AW. Identification of immunogenic, surface-exposed outer 
membrane proteins of Pasteurella haemolytica serotype l. 
20 Vet Microbiol 1999; 65: 215-26) High antibody responses to 
outer membranes, as measured by ELISA, and to several 
specific OMPs, as measured by quantitative Western Blot-
ting, consistently correlated with resistance to challenge 
with virulent M. haemolytica Sl (Confer AW, McCraw RD, 
25 Durham J A, Morton R J, Panciera R J. Serum antibody 
responses of cattle to iron-regulated outer membrane pro-
teins of Pasteurella haemolytica Al. Vet Immunol Immu-
nopathol 1995; 47:101-10 and Mosier DA, Simons KR, 
Confer AW, Panciera R J, Clinkenbeard K D. Pasteurella 
30 haemolytica antigens associated with resistance to pneu-
monic pasteurellosis. Infect Immun 1989; 57:711-6). Vac-
cination of cattle with OMP-enriched cellular fractions, 
from M. haemolytica S 1 significantly enhanced resistance of 
cattle against experimental challenge in the absence of 
35 antibodies to LKT. (Morton R J, Panciera R J, Fulton R W, 
Frank G H, Ewing SA, Homer J T, Confer AW. Vaccination 
of cattle with outer membrane protein-enriched fractions of 
Pasteurella haemolytica and resistance against experimen-
tal challenge exposure. Am J Vet Res 1995; 56: 875-879) 
40 However, the extraction procedure for bacterial outer mem-
branes is time consuming and expensive, making use of 
purified OMPs as a component of a M. haemolytica vaccine 
impractical due to cost. Thus, it can be appreciated that the 
identification of specific, surface exposed immunogenic M. 
45 haemolytica OMPs that would stimulate strong antibody 
responses is highly desirable. Cloning and expression of the 
appropriate gene(s) and production of recombinant OMP 
could be achieved inexpensively. 
One of the M. haemolytica OMP to which high antibody 
50 responses correlated with resistance against experimental 
challenge is a major 45 kDa OMP. Prior studies were 
undertaken to clone and characterize that protein. In 1998, 
Pandher et al. reported the cloning, sequencing and charac-
terization of the gene for the major 45-kDa M. haemolytica 
55 Sl outer membrane lipoprotein, designated PlpE. (Pandher 
K, Confer A W, Murphy G L. Genetic and immunologic 
analyses of PlpE, a lipoprotein important in complement-
mediated killing of Pasteurella haemolytica serotype l. 
Infect Immun 1998; 66: 5613-9, which publication is incor-
60 porated herein by reference) PlpE was found genetically to 
have 32-35% similarity to an immunogenic lipoprotein, 
OmlA, demonstrated in Actinobacillus pleuropneumoniae 
serotypes 1 and 5. Affinity-purified, anti-PlpE antibodies 
recognized an OMP in all serotypes of M. haemolytica 
65 except in serotype 11. In addition, PlpE was determined to 
be surface-exposed, and in complement-mediated killing 
assays, a significant reduction was observed in killing of M. 
US 7,144,580 B2 
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haemolytica when bovine innnune serum that was depleted 
of anti-PlpE antibodies was used as the source of antibody, 
suggesting that antibodies against PlpE may contribute to 
host defense against the bacterium. 
It was the object, then, of the present invention to inves- 5 
tigate the immunogenicity of recombinant PlpE and the 
potential for augmentation of existing vaccines to enhance 
protection against shipping fever. 
SUMMARY OF THE INVENTION 10 
4 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph depicting anti-PipE antibody response of 
6 cattle vaccinated with 100 µg of rPlpE on day 0. 
FIG. 2 is a bar graph depicting anti-PlpE antibody 
responses of cattle that spontaneously seroconverted to M. 
haemolytica (Natural Infection), vaccinated with connner-
cial vaccines, M. haemolytica outer membranes (OMP), or 
live M. haemolytica. 
FIG. 3 is a bar graph depicting anti-PlpE antibodies for 
cattle vaccinated with connnercial M. haemolytica vaccines 
or 100 µg of rPlpE. 
FIGS. 4A to 4C are a series of graphs depicting anti-PlpE 
In connection with the present invention, the gene for M. 
haemolytica outer membrane protein PlpE was cloned and 
the recombinant PipE (rPlpE) was purified and used in 
immunological and vaccination studies. It was discovered 
that adjuvanted rPlpE was highly innnunogenic in cattle, 
and vaccination of cattle with 100 µg of rPlpE markedly 
enhanced resistance against experimental challenge with 
virulent M. haemolytica. It was also discovered that the 
addition of rPlpE to a connnercial M. haemolytica vaccine 
significantly enhanced (p<0.05) protection afforded by the 
vaccine against experimental challenge. 
15 (A), anti-M. haemolytica leukotoxin (B), and anti-M. 
haemolytica whole cells (C) in cattle vaccinated with PRE-
SPONSE, PRESPONSE plus 100 µg of rPlpE, or nonvac-
cinated. 
FIG. 5 is a graph depicting rectal temperatures of calves 
20 after challenge. 
Thus, in one aspect of the present invention there are 
provided vaccine compositions comprising rPlpE or conser-
vatively modified variants thereof separately or which may 25 
optionally be combined with adjuvant to enhance the pro-
tection efficacy of vaccine preparations against BRD and/or 
shipping fever, wherein the vaccine composition further 
comprises a pharmaceutically acceptable carrier or diluent. 
The rPlpE also may optionally be combined with other 30 
immunogens and/or existing connnercially available vac-
cines to form a augmented vaccine composition, wherein the 
vaccine composition further comprises a pharmaceutically 
acceptable carrier or diluent and adjuvant. 
In another aspect of the invention there are provided 35 
methods for inducing an innnune response in cattle to 
provide innnune protection against BRD and/or shipping 
fever, the method comprising administering to an at-risk 
animal an effective amount of a vaccine composition com-
prising rPlpE or conservatively modified variants thereof 40 
alone or in combination with an adjuvant and/or other 
immunogens to provide a means to reduce the risk of BRD, 
wherein the vaccine composition further comprises a phar-
maceutically acceptable carrier or diluent. 
Most of the structure of an OMP molecule would play no 45 
significant role in inducing protective innnune responses, 
because extended portions of the molecule are buried, unex-
posed, in the outer membrane. Instead, innnunity can be 
attributed to only short, surface-exposed epitopes of these 
proteins. Identification of such surface-exposed epitopes as 50 
protective antigens in animal models has been the target of 
peptide vaccine design strategies for various pathogenic 
bacteria. Because of M. haemolytica PlpE's potential as an 
important innnunogen, we undertook these studies to char-
acterize surface-exposed and innnunologically important 55 
epitopes of PlpE and to produce and test recombinant 
epitopes corresponding thereto. 
Thus, in another aspect of the invention there are provided 
immunologically important epitopes of rPlpE for use in 
vaccines and related methodologies. 
A better understanding of the present invention, its several 
aspects, and its advantages will become apparent to those 
skilled in the art from the following detailed description, 
taken in conjunction with the attached figures, wherein there 
60 
is described the preferred embodiment of the invention, 65 
simply by way of illustration of the best mode contemplated 
for carrying out the invention. 
FIG. 6 is a graphical depicting of bovine antibody against 
surface exposed components of PipE that was affinity puri-
fied with intact M. haemolytica cells and used to probe a 
peptide array. Densitometric analysis demonstrated a total of 
8 distinct antigenic regions (El-8) in PlpE with E2 being the 
largest and E4 having the highest densitometric signal. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Before explaining the present invention in detail, 1t 1s 
important to understand that the invention is not limited in 
its application to the details of the embodiments and steps 
described herein. The invention is capable of other embodi-
ments and of being practiced or carried out in a variety of 
ways. It is to be understood that the phraseology and 
terminology employed herein is for the purpose of descrip-
tion and not of limitation. 
In accordance with the present invention there is provided 
a new vaccine against BRD and shipping fever through the 
use of discrete recombinant PlpE and subunits of rPlpE 
containing innnunoprotective regions. In one aspect, only 
rPlpE or innnunoprotective and functional regions thereof 
are utilized as the antigenic component of the vaccine. In 
another aspect, rPlpE or subunits thereof are utilized in 
combination with other antigen components, such as leuko-
toxin (LKT). Another aspect of the present invention relates 
to methods useful to reduce the risk of BRD and shipping 
fever in cattle and affect the biological transmission the 
disease among cattle populations. 
The experiments described and non-limiting examples 
provided hereinafter demonstrate that cattle innnunized with 
rPlpE and/or epitopes thereof are unexpectedly better pro-
tected against infection than cattle innnunized with existing 
connnercially available vaccines. 
EXAMPLE 1 
Innnunogenicity of rPlpE and Vaccine Preparation 
Studies were undertaken to determine the innnunogenic-
ity of outer membrane lipoprotein PlpE from M. 
haemolytica S 1, determine if connnercial vaccines stimulate 
antibodies to it, and examine if addition of recombinant PlpE 
to a connnercial M. haemolytica vaccine would augment 
vaccine-induced innnunity. 
US 7,144,580 B2 
1. Materials and Methods 
1.1. Bacterial Culture. 
5 
M. haemolytica Sl Oklahoma Strain was used for serol-
ogy antigen preparation and for challenge of animals. Fro-
zen stock cultures were plated onto brain-heart infusion 5 
(BHI) and grown at 37° C. in a 5% CO2 environment for 18 
hours. An isolated colony from each was propagated in 10 
ml BHI broth with rotatory shaking at 120 oscillations/min. 
for 18 hours at 37° C. One hundred µl of suspension was 
added to 1 L ofBHI broth and grown overnight. The bacteria 10 
were sedimented by centrifugation at 6000xg for 15 min-
utes, washed in 125 ml sterile phosphate buffered saline 
(PBS) and re-centrifuged as above 6000xg for 15 minutes. 
The bacteria were re-suspended in PBS and adjusted spec-
trophotometrically to a final concentration of approximately 15 
1.0xl09 CFU/ml (optical density of A600=0.65). 
1.2. Cloning and Purification of PlpE 
The truncated form of plpE lacking the sequence encod-
ing the putative signal peptide was amplified from pB4522 
(Pandher et. al., 1998, supra) with the help of a forward 20 
primer starting 58 nucleotides into the 5'-end and priming 
into the open reading frame of plpE and a reverse primer 
which is complementary to the 3'-end of the gene. The 
amplimer was cut with BamHI and HindIII and ligated into 
an expression vector, pRSETA, cut with the same restriction 25 
enzymes. Competent E. coli DH5a were transformed with 
the ligation mixture and transformants were plated on Luria-
Bertani (LB) agar plates with 50 µg/ml of ampicillin. Trans-
formants were screened and appropriate subclones were 
identified. Plasmid DNA isolated from such subclones was 30 
6 
metrically to be 1.850 OD650 . LKT was prepared from 
supernatant from a 3-hour culture of M. haemolytica Sl 
grown in RPMI-1640 medium at 37° C. in a shaking 
incubator. The LKT was partially purified by precipitation 
with 40-60% anmionium sulfate. The precipitate was resus-
pended in 3M guanidine containing 59 mM NaHPO4 and 
100 mM NaCl. By SDS-PAGE of the LKT preparation, one 
intensely staining band was identified at 105 kDa and 
confirmed to be LKT on a western blot using an anti-LKT 
monoclonal antibody. Lenkotoxic activity was 104 LKT 
Units per ml. The 2-keto-3-deoxyoctonate concentration 
was 7.5 µg per mg of protein. 
Wells of 96-well microtiter plates were coated with WC at 
an optical density reading equivalent to 108 CFU of a 
24-hour culture, with LKT at 50 ng per well, or with rPlpE 
at 50 ng per well. Sera were diluted in PBS-Tween 20 
containing 1 % BSA. ELISA for detection of serum antibod-
ies to PlpE was done in the first immunogenicity study using 
serum dilutions ranging from 1:400-1:819,200. Otherwise, 
sera were tested against various antigens at dilutions of 
1:800 for WC, 1:1600 for LKT, and 1:1600 for rPlpE, which 
were in the linear range of established dilution curves. The 
extent of antibody binding was detected using a 1 :400 
dilution of horseradish peroxidase-conjugated, affinity puri-
fied rabbit anti-bovine IgG (Kirkegaard & Perry Laborato-
ries, Gaithersburg, Md.). Antibody responses are expressed 
as ng of immunoglobulin binding based on a set of IgG 
standards on each plate. 
1.4. Animals 
A total of 82 normal healthy beef calves (Hereford or 
Angus/Hereford cross) of mixed sex were used. The calves 
were weaned at around 6-8 months of age. All calves were 
vaccinated with 7-way Clostridial vaccine and leptospiral 
vaccine, and treated with anthelmintic 30 days prior to the 
submitted to the Oklahoma State University Core Facility 
where the nucleotide sequence was determined by the ABI 
Model 3700 (BioSciences) automated DNA sequencing sys-
tem (SEQ ID NO: 1 ). Once the nucleotide sequence of a 
representative subclone was compared to that deposited in 
the GenBank (AF059036), the recombinant plasmid was 
introduced into BL21(DE3)pLysS by transformation to 
express and purify rPlpE (SEQ ID NO: 2). 
35 study. The calves received free choice native grass hay 
supplemented with grain ration throughout the study. All 
animal studies were done following using protocols 
approved the University Institutional Animal Care and Use 
The expression of rPlpE was done according to the 
protocol recommended by the manufacturer of the vector 40 
and the expression host (Invitrogen, CA). Briefly, single 
colonies of BL21 (DE3)pLysS harboring the truncated plpE 
Committee (Protocol #182). 
1.5. Anti-PlpE Responses with M. haemolytica Vaccines 
To determine if vaccination of cattle with commercial or 
experimental M. haemolytica vaccines stimulate anti-PlpE 
antibodies, two studies were done. The first experiment was 
a retrospective study using sera from 18 cattle from previous 
in pRSETA, were inoculated into appropriate volumes of LB 
broth with 50 µg/ml ampicillin and 34 µg/ml chlorampheni-
col. The culture were incubated at 37° C. until A600=0.5 was 
attained at which time the synthesis of the recombinant 
protein was induced by adding IPTG (1 mM final concen-
tration) and the induction was continued for at least 3 hours. 
In order to purify rPlpE, the culture was harvested and lysed 
by sonication. The cellular debris was then removed by 
centrifugation and the recombinant protein was loaded onto 
an affinity colunm packed by PROBOND nickel-chelating 
resin that selectively binds recombinant proteins with 6 
histidine residues (His-Tag) at either the N- or Carboxy-
terminus. In this instance, the His-Tag is at the N-terminus. 
The recombinant protein bound to the resin was then eluted 
with either a low pH buffer or competition with imidazole. 
The purity of each preparation was determined by SDS-
PAGE followed Coomassie stain and Western blot with 
murine anti-PlpE ascites fluid. 
1.3. Serology 
Antibodies to formalin-killed M. haemolytica whole bac-
terial cells (WC), to LKT, and to rPlpE were determined by 
enzyme-linked immunosorbent assays (ELISAs). For WC 
preparation, M. haemolytica Sl were prepared from a 
washed 24 hour culture by suspending cells in 0.4% forma-
linized saline at a concentration determined spectrophoto-
45 vaccine studies. Serum antibodies to PlpE were determined 
on samples from the day of vaccination (day 0) and from day 
14. On day 0, three calves each were vaccinated subcuta-
neously with one of the following commercial vaccines: P. 
haemolytica Toxoid, BRSV-BVD-IBR-PI3 Vaccine (PYRA-
50 MID™ 4/PRESPONSE®, Fort Dodge Laboratories), P. 
haemolytica-multocida Bacterin-Toxoid (PULMO-
GUARD™ PH-M, Boehringer Ingelheim), P. haemolytica-
multocida-Salmonella typhimurium Bacterin-Toxoid 
(POLY-BAC B® 1, Texas Vet Labs). Three calves were each 
55 vaccinated with 2 mg of an M. haemolytica outer membrane 
preparation in Freund's incomplete adjuvant or 109 CFU of 
live M. haemolytica. In addition, sera were analyzed from 
three non-vaccinated calves that spontaneously serocon-
verted to M. haemolytica based on positive antibody 
60 responses to WC and LKT. 
The second vaccine experiment was a prospective study 
designed to follow the anti-PlpE antibodies for 42 days after 
a single dose of a commercial M. haemolytica vaccine or 
rPlpE. Thirty calves were divided equally among 6 groups 
65 and vaccinated subcutaneously once each on day O with 
PRESPONSE®, P. haemolytica Bacterin-Toxoid (ONE 
SHOT™, Pfizer), an avirulent M. haemolytica culture 
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(ONCE PMH®, Intervet), PULMO-GUARD™ PH-M, or 
100 µg of rPlpE in connnercial adjuvant (Pfizer). Five 
unvaccinated calves served as controls. Sera were obtained 
on days 0, 7, 14, 21, 28, and 42, and antibodies to WC, LKT 
and PlpE were determined. 
1.6. Recombinant PlpE Innnunogenicity Studies 
To determine if rPlpE was innnunogenic, one calf each 
was vaccinated once with either 10, 50, or 100 µg of rPlpE 
in a connnercial proprietary adjuvant (Pfizer Inc, Lincoln, 
Nebr.). One calf remained as a non-vaccinated control. Sera 
were obtained 21 days after vaccination and evaluated for 
end-point antibody titers against rPlpE using serial 2-fold 
dilutions. Twenty-four days after the initial vaccination, 
each calf and a non-vaccinated calf were transthoracically 
challenged with 5.0xl09 CFU of live M. haemolytica from 
an overnight culture in accordance with established proce-
dures. Four days later, calves were humanely killed, and 
lung lesion scores determined on a 20-point scale. 
In a second cattle experiment, 6 cattle were vaccinated 
with 100 µg of rPlpE in connnercial adjuvant on day O and 
6 calves remained as non-vaccinated controls. On day 21, all 
cattle were challenged intrathoracically with lxl09 CFU of 
virulent M. haemolytica. Calves were humanely killed on 
day 25, and lung lesion scores determined. Antibody 
responses against rPlpE and M. haemolytica WC were 
determined on days 0, 7, 14 and 21 after vaccination. 
In a third cattle experiment, PRESPONSE® was obtained 
from the manufacturer, and 18 weanling beef steers were 
equally allocated among the following vaccine groups: 
Group 1-PRESPONSE, Group 2-PRESPONSE+ 100 µg 
PlpE, and Group 3-non-vaccinated. Cattle were vaccinated 
on day O with 2 ml of PRESPONSE (manufacturer's rec-
onnnended dosage) or 2 ml of PRESPONSE mixed with 0.5 
ml of PlpE (100 µg). Antibody responses to M. haemolytica 
WC, rPlpE or to LKT were determined by ELISA on days 
0, 7, 15, and 23. On day 24, cattle in Groups 1, 2, & 3 were 
challenged transthoracically with 3.0xl09 CFU of M. 
haemolytica. Four days later, calves were humanely killed, 
and lung lesion scores determined. 
1.7. Statistical Analysis 
Mean rectal temperatures, antibody responses and lesion 
scores among the various groups were compared by Stu-
dents t tests. Mean rectal temperatures and antibody 
responses within groups were compared by paired t tests. 
Differences were considered significant when p<0.05. Lin-
ear regression analyses were done to determine if there was 
a significant correlation between antibody response and 
lesion score. 
2. Results 
2.1. Recombinant PlpE Innnunogenicity 
In the first innnunogenicity experiment that determined 
end-point anti-rPlpE titers in response to various doses of 
rPlpE, serum from the non-vaccinated calf had an end-point 
antibody titer of 1 :400 against rPlpE. Sera from the 10, 50, 
and 100 µg vaccinates had titers of 1:12,800, 1:25,600, and 
8 
the nonvaccinated calves. Anti-LKT antibodies did not sig-
nificantly increase for either the rPlpE-vaccinated or control 
groups (data not shown). Mean lesion scores (±standard 
deviation) after challenge were 7.0±3.8 for nonvaccinated 
5 controls and 4.1±3.0 for the rPlpE vaccinates, a 41.4% 
reduction in lesion scores. Those differences were signifi-
cantly different at the level ofp=0.07. When data from the 
first experiment were combined with these data, the mean 
lesion score for nonvaccinated controls was 8.2±4.7 and 
10 mean lesion score for PlpE vaccinates was 3.9±2.6 (p<0.05), 
a 52.1 % reduction in lesion scores. 
2.2. M. haemolytica Vaccines 
In the first vaccine experiment, vaccination of calves with 
connnercial vaccines, M. haemolytica outer membranes, and 
15 live M. haemolytica resulted in a nonsignificant increase in 
antibodies to PlpE (FIG. 2). In contrast, natural exposure to 
M. haemolytica, as indicated by spontaneous seroconver-
sion, resulted in a significant increase in anti-PlpE antibod-
ies. All vaccine-induced responses and natural exposure 
20 were substantially less than the antibodies produced in a calf 
vaccinated with 100 µg of rPlpE in connnercial adjuvant. 
There were no significant differences among the antibody 
responses to rPlpE on day 14 for any of the connnercial 
vaccine, live M. haemolytica vaccinated, or natural exposure 
25 groups. Antibody responses to M. haemolytica LKT and WC 
significantly increased for PULMOGUARD- and the live 
bacteria-vaccinated and natural exposure calves, whereas 
vaccination with outer membranes stimulated a significant 
antibody response to WC and vaccination with POLY-BAC 
30 and PRESPONSE failed to stimulate significant antibody 
responses to either M. haemolytica antigen ( data not shown). 
In the second vaccine experiment, vaccination of calves 
with one of four connnercial M. haemolytica vaccines 
resulted in nonsignificant increases in antibodies to PlpE 
35 (FIG. 3). Vaccination of calves with 100 µg of rPlpE in 
connnercial adjuvant stimulated a significant increase in 
antibody responses to PlpE by day 7. That response contin-
ued to increase until it peaked on day 21 after vaccination. 
Vaccination with each commercial vaccine and with rPlpE 
40 resulted in significant increases in antibodies to M. 
haemolytica WC by day 7 (ONE SHOT and PRESPONSE) 
and by day 14 (ONCE PMH, PULMOGUARD, and rPlpE) 
(FIG. 2). Those responses remained significantly increased 
through day 14 (ONCE PMH and PRESPONSE) and day 42 
45 (ONE SHOT, PULMOGUARD, and rPlpE). Peak antibody 
responses for ONE SHOT-vaccinated cattle were signifi-
cantly greater than peak responses for ONCE PMH, PRE-
SPONSE or rPlpE vaccinates. Although antibody responses 
to LKT increased after vaccination with each connnercial 
50 vaccine, only the responses initiated by PULMOGUARD 
and ONE SHOT were significantly increased beginning on 
day 7 through day 28. Anti-LKT antibodies did not increase 
for the rPlpE vaccinates. Peak anti-LKT antibody responses 
for PULMOGUARD-vaccinated cattle were significantly 
55 greater than peak responses for ONCE PMH, PRESPONSE 
or rPlpE vaccinates, whereas peak anti-LKT antibody 
responses for ONE SHOT-vaccinated cattle were signifi-
cantly greater than peak responses for PRESPONSE vacci-
nates. 
1 :25,600, respectively. Intrathoracic challenge of those 
calves with virulent M. haemolytica resulted in a lesion 
score of 15.5 (20 maximum severity) for the non-vaccinated 
control calf. Lesion scores for the 10, 50, and 100 µg-vac- 60 
cinates were 4.5, 3.0, and 3.5 respectively. 
2.3. Augmentation of Connnercial Vaccine with rPlpE 
Because vaccination with connnercial M. haemolytica 
vaccines stimulated low antibody responses to rPlpE, we 
investigated the augmentation of a connnercial vaccine with 
rPlpE. Vaccination with PRESPONSE stimulated a signifi-
In the second immunogenicity experiment, vaccination 
with rPlpE on day O stimulates a significant increase in 
antibodies to rPlpE and to M. haemolytica WC on day 7 
(FIG. 1). Those responses continued to increase to a maxi-
mum on day 20 and declined insignificantly on day 25, 
whereas antibodies to rPlpE and to WC failed to increase for 
65 cant increase in anti-rPlpE antibodies on day 15. Those 
responses, however, were not significantly different than 
were antibody responses of the nonvaccinated control calves 
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on days 7, 15, and 23 (FIG. 4). PRESPONSE-rPlpE vacci-
nation stimulated a significant increase in anti-rPlpE anti-
bodies on days 7, 15 and 23, and those responses were 
significantly higher than responses for the PRESPONSE-
vaccinated or nonvaccinated control calves. Anti-WC and 5 
anti-LKT responses were significantly increased on days 7 
and 15 for the PRESPONSE- and PRESPONSE-rPlpE vac-
cinates. Those responses were not significantly different 
between those groups, whereas they were significantly 
greater than were anti-WC and anti-LKT antibody values for 1 o 
the nonvaccinated control group. 
10 
decreased clinical signs and pneumonic lesions. (Conlon J 
A, Shew en P E, Lo RY. Efficacy of recombinant leukotoxin 
in protection against pneumonic challenge with live Pas-
teurella haemolytica Al. Infect Immun 1991; 59: 587-91) 
Therefore, addition of one or more recombinant proteins to 
a M. haemolytica vaccine could be used by animal health 
companies to provide better products for protection of cattle 
against shipping fever. 
In a recent survey, researchers found that of the M. 
haemolytica isolates from bovine respiratory disease from 
upper Midwestern United States were 60% Al, 26% A6 and 
7% A2 with the remaining isolates from A9, All and 
untypable strains. (Al-Ghamdi GM, Ames TR, Baker JC, 
Walker R, Chase C C, Frank G H, Maheswaran S K. 
Serotyping of Mannheimia (Pasteurella) haemolytica iso-
lates from the upper Midwest United States. J Vet Diagn 
Invest 2000; 12: 576-8) In another study, 60% of M. 
haemolytica isolates from cattle in a Texas feedyard were 
Al, whereas 40% were serotypes A2, A6, or AS (Purdy C W, 
Raleigh R H, Collins J K, Watts J L, Straus D C. Serotyping 
and enzyme characterization of Pasteurella haemolytica and 
Pasteurella multocida isolates recovered/ram pneumonic 
lungs of stressedfeeder calves. Curr Microbial 1997; 34: 
244-9) Therefore, although serotype 1 is the most common 
isolate from shipping fever, other serotypes play a role in the 
disease. Currently available M. haemolytica vaccines con-
Rectal temperatures were taken on the day of challenge 
(day 24) and for the next 3 days (FIG. 5). Rectal tempera-
tures remained essentially normal for all cattle except for the 
nonvaccinated Control group. In that group, rectal tempera- 15 
tures significantly increased on days 25 and 26, declining 
insignificantly on day 27. On days 26 and 27, mean rectal 
temperatures for the nonvaccinated Control group were 
significantly greater than for either the PRESPONSE or 
PRESPONSE/rPlpE groups. At necropsy, mean lung lesion 20 
scores were 7.9±3.6 for nonvaccinated controls, 3.0±1.3 for 
PRESPONSE-vaccinates (62.0% reduction in lesion score), 
and 1.1±0.9 for PRESPONSE/rPlpE vaccinates (86.1 % 
reduction in lesion scores). Differences between the PRE-
SPONSE and Control and PRESPONSE/PlpE and Control 25 
lesion scores were significant. In addition, mean lesion score 
for the PRESPONSE/PlpE group was significantly lower 
than for the PRESPONSE group. There was a significant 
correlation (r=-0.598, p<0.01) between high serum antibody 
responses to rPlpE at day 23 and low lesion scores. 30 tain serotype 1 exclusively and therefore may or may not 
3. Discussion 
The foregoing studies demonstrate that rPlpE is highly 
immunogenic for cattle and that vaccination with rPlpE can 
greatly enhance resistance against experimental challenge 35 
with the bacterium. The in vivo studies definitively indicate 
that anti-PlpE antibodies can contribute to host defense 
against M. haemolytica infection. 
Vaccination of cattle with commercial M. haemolytica 
vaccines, live M. haemolytica or outer membranes or after 40 
prior natural exposure stimulated low antibody responses to 
PlpE. For those vaccines, the rise in antibodies to rPlpE as 
measured on various days were not significant, and even 
those vaccines that stimulated high antibodies to M. 
haemolytica WC and LKT still stimulated low anti-rPlpE 45 
response. Commercial vaccine-induced anti-rPlpE antibody 
responses were substantially lower than those stimulated by 
vaccination with 100 µg of rPlpE in a commercial adjuvant. 
This was not unexpected, because commercial vaccines vary 
greatly in their composition in that some are composed of 50 
culture supernatants and bacterial cell components, others 
contain whole bacterial cells, and one is a live mutant. A 
somewhat surprising finding was that calves previously 
vaccinated with M. haemolytica outer membranes in Fre-
und' s incomplete adjuvant had low antibody responses to 55 
rPlpE on day 14 (see Morton et al., supra). Therefore, 
although PlpE is a major outer membrane protein, its con-
centrations in commercial and experimental vaccines are 
most likely low and variable. In addition, the adjuvant used 
may play an important role in stimulating antibodies to PlpE. 60 
Because commercial vaccines stimulated low antibodies 
to PlpE, we used rPlpE to augment the antibody response of 
a commercial vaccine, PRESPONSE, and demonstrated that 
PRESPONSE/PlpE stimulated greater protection against 
challenge than did PRESPONSE alone. Conlon et al. pre- 65 
viously demonstrated that addition of recombinant LKT 
enhanced the efficacy of a culture supernatant vaccine and 
provide efficacious immunity against other serotypes. Cross 
serotype protection as stimulated by outer membrane vac-
cines or bacterins is limited. It is known that antibodies 
against M. haemolytica serotypel LKT will cross neutralize 
the toxin prepared from other serotypes. Therefore, com-
mercial vaccines that stimulate anti-LKT antibodies should 
provide some cross protection against other serotypes. How-
ever, Conlon et al. (supra) demonstrated that vaccination 
with recombinant LKT alone failed to stimulate protection 
against experimental M. haemolytica challenge, and Purdy 
et al (Purdy CW, Straus DC, Struck D, Foster G S. Efficacy 
of Pasteurella haemolytica subunit antigens in a goat model 
ofpasteurellosis. Am J Vet Res 1993; 54:1637-47) found 
that vaccination of goats with LKT-impregnated agar beads 
stimulated incomplete immunity. Shewen and Wilkie (Sh-
ewen PE, Wilkie B N. Vaccination of calves with leukotoxic 
culture supernatant from Pasteurella haemolytica. Can J Vet 
Res 1988; 52:30-6) demonstrated that immunity to M. 
haemolytica was directed against both surface antigens and 
LKT. The actual surface antigen of importance in stimulat-
ing protection is not known for sure; however, studies 
indicate that it is most likely outer membrane proteins and 
not capsular polysaccharide or lipopolysaccharide. Pandher 
et al. (supra) demonstrated the presence of a PlpE-like 
protein in outer membranes of all M. haemolytica serotypes 
except serotype 11, an uncommon isolate from shipping 
fever. There was some variation in molecular masses among 
the various proteins. With the current findings, demonstrat-
ing immunogenicity of rPlpE and augmentation of a com-
mercial vaccine that stimulates anti-LKT antibodies, the 
previous demonstration of a PlpE-like protein in most sero-
types and that anti-LKT antibodies can neutralize LKT from 
other serotypes, the addition of rPlpE to a commercial 
vaccine that stimulates anti-LKT antibodies could enhance 
cross serotype protection in shipping fever. 
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EXAMPLE 2 
Additional studies were undertaken to characterize sur-
face-exposed and immunologically important epitopes of 
rPlpE. 
1. Materials and Methods 
1. 1. Construction and Purification of Truncated Forms of 
rPlpE 
Three additional rPlpE proteins carrying varying degrees 
of deletions were constructed in pET28 and purified accord-
ing to the method described above. The first of these was 
obtained by using plpBM-1 (5'-CTTGGATCCCAAGCA-
CAAAATGTT-3') (SEQ ID NO: 3), a primer that primes 84 
bp into the 5'end ofplpE thus introducing a deletion of 28 
amino acids into the N-terminus end ofrPlpE (rPlpEllN28), 
the rd by plpBM-2 (5'-CCTGGATCCCAAGCAGAGGT-
TACT-3') (SEQ ID NO: 4), which primes 228 bp into the 
5'end of plpE introducing a 76 amino acid deletion in the 
N-terminus of rPlpE (rPlpEllN76), and the 3rd with 
plpBM-3 (5'-ATTGGATCCAATGCTGAACAACTC-3') 
(SEQ ID NO: 5) that primes 450 bp into 5'end of plpE 
introducing a deletion of 150 amino acids into the N-termi-
nus in of rPlpE (rPlpEllN150). The reverse primer in all 
instances was plpEER, (5'-GACTGAATTCT-
TATTTTTTCTCGCTAACCATTA-3') (SEQ ID NO: 6). 
1.2. Production of Polyclonal Mouse Ascites 
Three female, CFW mice were immunized 3 times with 
12 
flow thru was re-applied to the column several times to 
re-extract the serum by connecting the flow through to the 
reservoir of the initial serum. The colunm was then washed 
with DPBS. The complete removal of nonspecific proteins 
5 was determined with the help of the UV monitor attached to 
a chart recorder. Once there was no indication of nonspecific 
protein in the flow through, the specifically bound antibody 
was eluted with 100 mM Glycine Buffer (100 mM Glycine, 
140 mM NaCl, pH 3.0) by collecting fractions in microfuge 
10 tubes containing ½o vol of 1 M Tris-HCl, pH 8.0. The 
absorbance of each fraction was determined at 280 nm. 
Those fractions that had a reading at least 2-3 times the 
background were pooled and dialyzed overnight against 
DPBS at 4° C. in a SLIDE-A-LYZER Dialysis Cassette 
15 (Pierce, Rockford, Ill.). The concentration of affinity purified 
antibody was determined with BCA Protein Assay Kit 
(Pierce, Rockford, Ill.). More specific antibodies against 
rPlpE with 28, 76 and 150 amino acids deletions on their 
N-termini, rPlpEllN28 (pSAC63), rPlpEllN76 (pSAC64) 
20 and rPlpEllN150 (pSAC65), respectively, were purified as 
described. 
Antibodies against regions of PlpE that are exposed on the 
surfaces of M haemolytica cells were purified as described 
by Turbyfill et al., (1998). Briefly, intact M haemolytica cells 
25 from the late log phase were incubated with hyperimmune 
bovine sera immunized by rPlpE or anti-PlpE mouse ascites 
diluted in PBS on ice for 2-4 hr with gentle agitation. The 
cells were spun down and washed several times with PBS. 
The antibodies bound to the surface were eluted by resus-50 µg of complete or truncated rPlpE diluted by half in RIBI 
(Corixa Corp, Seattle, Wash.) adjuvant. The first immuni-
zation was done subcutaneously (SC). Subsequent immuni-
zations were done intraperitoneally (IP). A test-bleed was 
performed and the serum screened for antibodies to rPlpE by 
ELISA. The response was moderate, so two additional 
immunizations were performed IP. The mice were then 35 
injected with approximately 2xl06 sarcoma cells (ATCC 
cat# TIB-66). Between 7 and 10 days after sarcoma injec-
tion, the mice started producing ascites. Ascites fluid was 
removed from each mouse three times; mice were then 
euthanized by barbiturate overdose. 
30 pending and agitating the cells in 0.lM Glycine, 140 mM 
NaCl, pH 3.0 for at least 30 minutes. The cells were 
centrifuged at 13,000xg, and the eluted antibodies were 
collected in the supernatant which was neutralized immedi-
ately by adding 1/10 volume of 1 M Tris, pH 8.0. 
1.4. Epitope Mapping of PlpE by Peptide Array (Pepscan) 
A peptide array comprising a total of 109 overlapping 
13-mer peptides with 3 amino acid offsets was custom made 
by Sigma-Genosys LP (The Woodlands, Tex.). Briefly the 
synthesis of peptides was performed on cellulose mem-
40 branes in which hydroxyl functions of a commercially 
available filter paper are derivatized with 9 fluorenyl-
methoxycarbonyl-B-alanine (Fmoc-B-Ala) with subsequent 
removal of the Fmoc group. The synthesis areas were 
defined by spotting a Fmoc-B-alanine-pentafluorophenyl 
1.3. Preparation of Affinity Colunms and Purification of 
Anti-PlpE Antibodies 
Purified rPlpE was coupled to NHS-activated Sepahrose 4 
Fast Flow (Amersham Biosciences, Upsala, Sweden) 
according to the manufacturer's recommendation. Briefly, 
3-7 mg of rPlpE in PBS was mixed with 2 ml bed volume 
of washed and equilibrated NHS-activated Sepharose 4 Fast 
Flow in an Econo Colunm (BioRad, Hercules, Calif.), 
incubated at 4° C. overnight at which time the non-reacted 
groups were blocked by 0.1 M Tris pH 8.0, and washed with 
alternating high and low pH buffers, Tris, pH 8.0 and acetate 
buffer pH 4.0, respectively. Several affinity colunms were 
prepared with rPlpE carrying varying degrees of truncation 
from the N-terminus. 
Anti-rPlpE antibodies against specific regions of PlpE 
were purified using the affinity colunms described above. 
The ECONO-COLUMN with NHS-activated Sepharose 
coupled to an rPlpE of interest was fitted with a Flow 
adaptor according to the recommendation of the manufac-
turer (BioRad, Hercules, Calif.). The affinity colunm was 
equilibrated by applying Dulbecco's Phosphate Buffered 
Saline (DPBS) at a flow rate of 1 ml/min. Hyperimmune 
serum produced by immunizing calves with the intact rPlpE 
was mixed with DPBS in a ratio of 1 to 10 and passed 
through Nalgene 0.45 µm PES filters (Nalge, Rochester, 
N.Y.). The filtered serum was then applied to the equilibrated 
colunm via peristaltic pump at a flow rate of 1 ml/min. The 
45 ester solution to distinct areas on the membrane. Blocking 
the remaining amino functions between spots provided 
discrete reaction sites on the membrane for further standard 
solid phase peptide synthesis using amino acid pentafluo-
rophenyl esters. Peptides remained covalently attached to 
50 the cellulose membrane by the C-terminus and have a free 
N-terminus. 
The peptide array was probed with anti-PlpE hyperim-
mune sera as follows. Prior to blotting, membranes with the 
custom spots were blocked with SUPERBLOCK Dry Blend 
55 (Pierce, Rockford, Ill.) blocking buffer in TBS, pH 7.4. The 
membrane was then incubated in blocking buffer containing 
a primary antibody at a dilution of 1: 1000 to 1: 5000 for an 
hour. Following several washes with TBS, pH 7.4, supple-
mented with 0.05% TWEEN-20, 0.2% TRITON-X-100 
60 (TBSTT), the membrane was incubated in SUPERBLOCK 
containing a goat anti-bovine or anti-mouse secondary anti-
body conjugated to Horse Radish Peroxidase (KPL, Gaiths-
burg, Md.) at dilutions 1: 100,000 to 1 :200,000 for one hour. 
The membrane was washed several times with TBSTT. The 
65 peptide array was incubated with SuperSignal West Pico 
Chemiluminescent Substrate working solution (0.125 
ml/cm2) for 5 minutes, placed in plastic membrane protector 
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and exposed to a CL-X Posure (Pierce, Rockford, Ill.) 
X-Ray film for varying durations of time. The X-Ray film 
was then developed in a KONICA SRX-101A Medical Film 
Processor (Taiwan). The developed X-Ray film was scanned 
14 
(rPlpEllN28) with 28 amino acid deletions on the N-termi-
nus. The reactivity of pSAC64 (rPlpEllN76), which carries 
a deletion of 76 amino acids on the N-terminus, drops to 
63%, which is a 37% loss in signal intensity, when compared 
to rPlpE. Further deletion into the N-terminus as seen in 
pSAC65 (rPlpEllN150) reduces the binding capacity of the 
truncated proteins by 60%. These findings clearly suggest 
that the region between residues 28 and 76 from the N-ter-
minus of PlpE carries a stretch of amino acids with possible 
epitope(s) that may be responsible for invoking the immune 
response elicited when rPlpE is used as a vaccine. 
2.2. Fine Mapping of Epitopes on PlpE 
Putative antigenic regions in PlpE were identified by 
using the MACVECTOR 7.0 software that employed algo-
by ARCUS 1200 AGFA scanner (Taiwan), and scanned 5 
images were analyzed using GENEPIX Pro 4.0 (Axon 
Instruments, Union City, Calif.). Signal intensities were 
defined as median pixel intensity following subtraction of 
local median background signal. The peptide array was 
stripped with RESTORE™ Western Blot Stripping Buffer 10 
(Pierce, Rockford, Ill.) according to the procedure recom-
mended by the manufacturer before it was probed with a 
different anti-PlpE antibody. This was repeated several times 
with anti-PlpE antibodies obtained from different sources or 
purified in varieties of ways. 15 rithms such as antigenic index, hydrophilicity and surface 
probability. However, the identification of epitopes was 
done with a peptide array comprising 109 overlapping 
13-mer peptides that were synthesized by the chemistry 
described earlier. The peptides were covalently bound to 
2. Results 
2.1. Epitope Mapping of PlpE 
The determination of the epitope map of PipE was 
attempted in two steps. The first approach involved the 
localization of the general area of immunogenic or immu-
nodominant epitopes by deleting specific regions of PlpE 
from both the N-Terminus and C-Terminus by PCR with the 
help of specific primers. A total of 6 plasmid constructs 
carrying the plpE gene with varying degrees of deletions 
were made. The cloning of three of these constructs that 
carry deletions from the N-termini of PlpE, (pSAC63, 
pSAC64, and pSAC65) is described above. Three additional 
plasmids viz., pSAC30, pSAC31, and pSAC32 that carry 
106(rPlpEllC106), 96(rPlpEllC96) and 86 (rPlpEllC86) 
amino acid deletions on the C-terminus of PlpE, respec-
tively, were designed and constructed. The reverse primers 
used to introduce these deletions on the 3'end of the plpE 
gene in the latter constructs were HNplp-1(5'-
GATAAGCTTTTACCGTGCGGCAAATTC-3') (SEQ ID 
NO: 7), HNplp-2 (5'-AAAAAGCTTTTATTTAATTTCTA-
CATC-3') (SEQ ID NO: 8), and HNplp-3 (5'-TTTAAGCTT-
TATATACTTCCTTGAGC-3') (SEQ ID NO: 9), respec-
tively, and a forward primer plpEBH, (5'-
GTCAGGATCCTGCGGAGGAAGCGGTAGC-3') (SEQ 
ID NO: 10). Amplimers were cut with BamHI and HindIII 
and cloned into pET28 or pRSETA cut with the same 
enzymes. Following confirmation of the identity of putative 
clones by both restriction analysis and sequencing, plasmids 
from true clones were introduced into BL21(DE3) by trans-
formation where the truncated forms of PlpE were overex-
pressed and purified according to the protocol described 
earlier. The 6 truncated forms of rPlpE and the intact form 
were separated on a 12.5% SDS-PAGE for Western analysis. 
Hyperimmune serum from calves immunized with the intact 
rPlpE was used as primary antibodies and goat anti-bovine 
alkaline Phosphatase conjugated antibodies as secondary 
antibodies. Densitometric analysis of the respective bands in 
a Western blot in which the same amount of the recombinant 
proteins were loaded onto an SDS-PAGE and probed with 
hyperimmune serum from a calf that was immunized with 
rPlpE clearly showed that there are significant differences 
amongst recombinant proteins carrying deletions in the 
intensity of their reaction to the hyperimmune serum. 
Accordingly there is no difference in the intensity of binding 
between rPlpE and mutants with the deletions from the 
C-terminus viz., pSAC30, pSAC31, and pSAC32 that carry 
106(rPlpEllC106), 96(rPlpEllC96) and 86 (rPlpEllC86) 
amino acid deletions on the C-terminus of PlpE, respec-
tively. The binding capacity of mutants carrying deletions on 
their N-termini decreases with increasing deletions. There is 
no appreciable difference between rPlpE and pSAC63 
20 derivatized cellulose membrane by the C-terminus and have 
a free N-terminus. Anti-PlpE hyperimmune antibodies puri-
fied by any number of the methods described earlier were 
used to probe the peptide array. The custom spots were 
stripped and probed several times. When bovine antibody 
25 against surface exposed components of PipE that was affin-
ity purified with intact M. haemolytica cells was used to 
probe the peptide array a total of 8 distinct regions (El-8) 
were identified. (FIG. 6.) Epitope 1 (PNHPKPVLVPK-
TQNNL) (SEQ ID NO: 11) spans 3 peptides; epitope 2 
30 (QNASQAQNAPQAQNAPQAQNAPQVE-
NAPQAQNAPQVENAPQAE) (SEQ ID NO: 12), 11 pep-
tides; epitope 3 (GSFDKIGSVKLNK) (SEQ ID NO: 13), 3 
peptides; epitope 4 (KLGTPPKFDKVSGKKIIEE) (SEQ ID 
NO: 14), 6 peptides; epitope 5 (LIRRSDDLFYGYY) (SEQ 
35 ID NO: 15), 3 peptides; epitope 6 (ADKFSQYFVVYDE) 
(SEQ ID NO: 16), 3 peptides; epitope 7 (NISDKL-
TATYRKK) (SEQ ID NO: 17), 2 peptides; and epitope 8 
(PHTKEFAARISKL) (SEQ ID NO: 18). More or less the 
same set of epitopes, albeit with decreasing intensities, were 
40 picked up when whole serum obtained from cows with a 
naturally high anti-PlpE antibody titer that were also chal-
lenged with live M. haemolytica was used. The signal 
intensities of all of the epitopes with the exception of epitope 
2 were much lesser in this blot than in the earlier. The 
45 purification of IgG from the latter serum with Protein G 
affinity colunms did not alter the above result in that exactly 
the same putative epitopes were identified suggesting that 
IgG was the class of immunoglobulins involved in this 
immune response. When whole hyperimmune serum from 
50 calves immunized with rPlpE was used to probe the stripped 
peptide array exactly the same set of peptides mentioned 
above were identified once again confirming the binding 
capacity of the above indicated stretches of amino acids 
along PlpE. On the other hand, when sera from calves that 
55 were given live M. haemolytica were used to probe the 
peptide array, epitope 2 was the only one that was picked up. 
According to the manufacturers of the custom spots, non-
specific binding of the antibody-enzyme conjugate may 
occur to peptides that contain combinations of basic amino 
60 acids. When goat anti-bovine-HRP, the secondary antibody 
used in this project, was used to probe the spots, epitopes 1, 
3, 4, 7, and 8 were picked up. The same sets of epitopes were 
identified when the array was probed with rabbit anti-
bovine-HRP, showing putative epitopes 1, 3, 4, 7, and 8 were 
65 not true epitopes. In order to identify spots that would 
non-specifically bind bovine immunoglobulins, serum from 
colostrum deprived new born calf was used to probe the 
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array. Interestingly, in addition to the putative epitopes 
identified by the secondary antibody-enzyme conjugates, 
i.e., 1, 3, 4, 7, and 8, epitopes 5, and 6 exhibited reactivity 
16 
The nucleotide sequences used to generate the antigens 
may be inserted into any of a wide variety of expression 
vectors by a variety of procedures. Such procedures and 
others are deemed to be known by those skilled in the art. to bovine immunoglobulins. Epitope 2 was the only one that 
did not react to both the serum from the colostrums deprived 
calf and secondary antibody-enzyme conjugate showing that 
this epitope is the only one responsible for inducing the 
specific immune response when calves were either vacci-
nated with rPlpE or M. haemolytica. 
A closer examination of epitope 2 shows that this is part 
of the region identified as having 8 imperfect repeats of 
hexapeptides (Pandher et. al., 1998). The 11 peptides (#13 
through 23) identified here as epitope 2 comprise the last 4 
residues of the 2nd repeat described by Pandher et al., (1998) 
and the rest of the repeats i.e., repeats 3 through 8 with the 
exception of the 1st hexapeptide. A feature of these 11 
peptides is the lack of uniformity in their binding capacity as 
evidenced by the variation in their signal intensities. Pep-
tides #15, 17, and 19 exhibit the highest signal intensities 
followed by #s 21 and 23. The first 4 residues of the 
N-termini of these peptides are Q, N, A and P, with the 
exception of #21 in which the first glutamine is replaced by 
glutamate. It is worthwhile noting that both glutamine and 
aspargine are positively charged, with hydrophobicity index 
5 Suitable vectors include chromosomal, nonchromosomal 
and synthetic DNA sequences; e.g., derivatives of SV 40; 
bacterial plasmids; phage DNAs; yeast plasmids; vectors 
derived from combinations of plasmids and phage DNAs, 
viral DNA such as baculovirus, vaccinia, adenovirus, fowl 
10 pox virus, pseudorabies, etc. The appropriate DNA sequence 
must be operatively linked in the vector to an appropriate 
expression control sequence(s) (promoter) to direct mRNA 
synthesis. As representative examples of such promoters, 
15 there may be mentioned LTR or SV 40 promoter, the E. coli 
lac or trp, the phage lambda PL promoter and other promot-
ers known to control expression of genes in prokaryotic and 
eukaryotic cells or their viruses. The expression vector also 
includes a non-coding sequence for a ribosome binding site 
20 for translation initiation and a transcription terminator. The 
vector may also include appropriate sequences for amplify-
of -0.91 and -0.92, respectively. The remaining 6 peptides 25 
in epitope 2 have praline at their N-termini instead of 
glutamine and this may account for their relatively lower 
signal intensity in the peptide array. The relatively high 
signal intensities exhibited by peptides 15, 17, and 19 may 
reflect the manner in which these epitopes are presented to 30 
the immune system under natural condition on the surfaces 
of M. haemolytica cells and the inherent immunogenic 
nature of these stretches of amino acids. The fact that epitope 
2 contains significant number of pro lines at defined intervals 
which are usually indicators of turns, has an unusually high 35 
number of very basic residues such as glutamine, aspargine 
and glutamate which are hydrophilic with high surface 
probability and 8 repeats are features that are usually asso-
ciated with regions of protein that are associated with being 
immunogenic. Moreover, computer analysis of the deduced 40 
amino acid sequence of epitope 2 with algorithms such as 
Parker's antigenicity, Kyte/Doolittle hydrophilicity, surface 
probability and Chou Fasman D 0 structure indices show that 
the stretch of amino acids has a moderatly high antigenicity, 
fairly hydrophilic, contains fairly high number of amino 45 
acids with very high surface probability and is characterized 
by series of turns associated with helices and sheets, respec-
tively, all of which are strong indicators of a region that is 
potentially highly immunogenic. 
ing expression. 
The vector containing an appropriate sequence, as well as 
an appropriate promoter or control sequence, may be 
employed to transform an appropriate host to permit the host 
to express the protein. Examples of host organisms and cells 
include bacterial strains ( e.g., E. coli, Pseudomonas, Bacil-
lus, Salmonella, etc.), fungi (e.g., yeasts and other fungi), 
animal or plant hosts (e.g., mouse, swine or animal and 
human tissue cells). The selection of the host is deemed to 
be within the scope of those skilled in the art. 
As previously mentioned, it is also understood that the 
appropriate sequence present in the vector when introduced 
into a host may express part or only a portion of the protein 
which is encoded within the noted terminology, it being 
sufficient that the expressed protein be capable of eliciting an 
antibody or other immune response which recognizes an 
epitope(s) of the listed amino acid sequences. 
The isolated polypeptides expressed by the host trans-
formed by the vector may be harvested by methods which 
will occur to those skilled in the art and used in a vaccine for 
providing an enhanced immune response against infection 
with M. haemolytica. Vaccine preparation is easily accom-
plished using well known methods and techniques. An 
enhanced immune response is manifest by protection against 
infection or a decrease in severity of infection, which may 
be reflected in body temperature and antibody titers as 
described above. 
The host expressing the antigen may itself be used to 
deliver antigen to non-human animals, by introducing killed 
or viable host cells that are capable of propagating in the 
animal. Direct incorporation of the nucleotide sequences 
Accordingly, it can be appreciated that subunits derived 50 
from PlpE, and especially epitope 2, are useful as well in the 
inventive vaccine compositions and methodologies. The 
inclusion of such region(s) enhances the host immune 
response directed against relevant immunoprotective 
epitopes. 
It accordingly can be appreciated that the inventive vac-
cines utilize as distinct antigenic components rPlpE or 
subunits thereof capable of eliciting an antibody or other 
immune response against M. haemolytica. As a result, the 
invention encompasses proteins which may be the full 60 
length antigen, antigen fragment, antigen derivative or a 
fusion product of such antigen, antigen fragment or antigen 
derivative with another protein. Proteins included within the 
present invention include those depicted in the Sequence 
Listing as well as mutuants of said sequences capable of 65 
eliciting an antibody or other immune response which 
recognizes an epitope(s) of such amino acid sequences. 
55 into host cells may also be used to introduce the sequences 
into animal cells for expression of antigen in vivo. 
Vaccine preparations are combined with physiologically 
acceptable carriers to form vaccines. The carrier employed 
in conjunction with vaccine may be any one of a wide 
variety of carriers. As representative examples of suitable 
carriers, there may be mentioned mineral oil, synthetic 
polymers, etc. Carriers for vaccines are well known in the art 
and the selection of a suitable carrier is deemed to be within 
the scope of those skilled in the art. The selection of a 
suitable carrier is also dependent upon the manner in which 
the vaccine is to be administered. The preferred physiologi-
cally acceptable carrier is an adjuvant. 
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Preferably, the inventive vaccine formulation is set to 
contain 10-100, and preferably about 100, micrograms of 
recombinant antigens in commercially available adjuvant 
(Pfizer). 
The vaccines may be administered by a variety of routes 5 
including intravenously, intraperitoneally, intramuscularly, 
and subcutaneously. The preferred route of administration is 
subcutaneous. Alternatively, the vaccine may be adminis-
tered intranasally or orally. The vaccine can be administered 
geous results attained. As various changes could be made in 
the above sequences, antigens, etc. without departing from 
the scope of the invention, it is intended that all matter 
contained in the above description or shown in the accom-
panying drawings shall be interpreted as illustrative and not 
in a limiting sense. 
in a single dose or multiple doses until a protective effect is 10 
achieved. 
In view of the above, it will be seen that the several 
objectives of the invention are achieved and other advanta-
<160> NUMBER OF SEQ ID NOS: 18 
<210> SEQ ID NO 
<211> LENGTH: 1310 
<212> TYPE: DNA 
SEQUENCE LISTING 
<213> ORGANISM: Mannheimia haemolytica 
<300> PUBLICATION INFORMATION: 
<301> AUTHORS: Pandher et al. 
While the invention has been described with a certain 
degree of particularity, it is understood that the invention is 
not limited to the embodiment(s) set for herein for purposes 
of exemplification, but is to be limited only by the scope of 
the attached claim or claims, including the full range of 
equivalency to which each element thereof is entitled. 
<302> TITLE: Genetic and Immunologic Analyses of PlpE, a Lipoprotein 
Important in Complement-Mediated Killing of Pasteurella 
haemolytica Serotype 1 
<303> JOURNAL: Infection and Immunity 
<304> VOLUME: 66 
<305> ISSUE: 12 
<306> PAGES: 5613-5619 
<307> DATE: 1998-12 
<400> SEQUENCE: 1 
agggctaatc tactacagcc ccaaaaattt tcataaggga aacgtttacg taaaactcct 60 
cagaccactc attcttattt tatataaaaa atgtgataga cttctcgcag tttcgtttta 120 
tatatttaag gaataactaa gtgaaattca ataaaaaatt aattttaaca tttgctgcaa 180 
ccttagtttt aagtgcttgc ggaggaagcg gtagcggagg ttcgtcttca acaccgaatc 240 
accccaaacc agtactagta ccaaaaacac aaaataatct tcaagcacaa aatgttcctc 300 
aggcacaaaa tgcctctcag gcacaaaatg cccctcaggc acaaaatgct cctcaggcac 360 
aaaatgctcc tcaggtggaa aatgctcctc aggcacaaaa tgctcctcag gtagaaaatg 420 
ctcctcaagc agaggttact ccgcctgtac cacagccaca atcacaaaaa attgacggtt 480 
cttttgataa aattggttca gtaaaactca ataaagaggc tcaaactctt gagcttagta 540 
gattcacttt ggtggataaa ttaggcacac caccgaagtt tgataaagta agcggtaaaa 600 
aaattattga agaaaaagat tttctcgtat taaatttgtc tgatattaat gctgaacaac 660 
tctctggcga ttttcttatt cgccgtagcg atgatctatt ctatggctac tatcacgata 720 
caaatggcaa aaatcttgtc gatgctgccg ataaattcag tcaatatttt gtcgtgtatg 780 
atgagaaacg ggtaaatgat aatatctctg ataaattaac agcaacttac cgtaaaaaag 840 
aaggctttgt atatggttca aatccacata ctaaagaatt tgccgcacgg atcagcaaat 900 
tgggggatgt agaaattaaa tttgaaaatg gtcaagctca aggaagtata aaagacgaaa 960 
aagatggaaa tgctgagatc tttactatta aaggtgatac aaaacagtta gagattaccc 1020 
caacggaaag taaccgaatc attatagcaa ttttagacca aaatcaaaaa agctatactc 1080 
caggaatgga aaaagcaatt atggaaacta agtttattga ttcaaaggct ggtaattccg 1140 
accaaaaata cttaatcggt gaagcaaaaa gcgataactg gcaagcaata atggttagcg 1200 
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-continued 
agaaaaaata aagttatctt ttgctaaaaa ctgaaataaa aaggctgagt ccgggtaata 1260 
tcggcctcag tcttttaaat tgtagaaaat catctgtaga agatcaaacc 1310 
<210> SEQ ID NO 2 
<211> LENGTH: 337 
<212> TYPE: PRT 
<213> ORGANISM: Mannheimia haemolytica 
<300> PUBLICATION INFORMATION: 
<301> AUTHORS: Pandher et al. 
<302> TITLE: Genetic and Immunologic Analyses of PlpE, a Lipoprotein 
Important in Complement-Mediated Killing of Pasteurella 
Haemolytica Serotype 1 
<303> JOURNAL: Infection and Immunity 
<304> VOLUME: 66 
<305> ISSUE: 12 
<306> PAGES: 5613-5619 
<307> DATE: 1988-12 
<400> SEQUENCE: 2 
Cys Gly Gly Ser Gly Ser Gly Gly Ser 
1 5 
Lys Pro Val Leu Val Pro Lys Thr Gln 
20 25 
Ser 
10 
Asn 
Ser Thr Pro Asn His Pro 
15 
Asn Leu Gln Ala Gln Asn 
30 
Val Pro Gln Ala Gln Asn Ala Ser Gln Ala Gln Asn Ala Pro Gln Ala 
35 40 45 
Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Val Glu Asn Ala Pro 
50 55 60 
Gln Ala Gln Asn Ala Pro Gln Val Glu Asn Ala Pro Gln Ala Glu Val 
65 70 75 80 
Thr Pro Pro Val Pro Gln Pro Gln Ser Gln Lys Ile Asp Gly Ser Phe 
85 90 95 
Asp Lys Ile Gly Ser Val Lys Leu Asn Lys Glu Ala Gln Thr Leu Glu 
100 105 110 
Leu Ser Arg Phe Thr Leu Val Asp Lys Leu Gly Thr Pro Pro Lys Phe 
115 120 125 
Asp Lys Val Ser Gly Lys Lys Ile Ile Glu Glu Lys Asp Phe Leu Val 
130 135 140 
Leu Asn Leu Ser Asp Ile Asn Ala Glu Gln Leu Ser Gly Asp Phe Leu 
145 150 155 160 
Ile Arg Arg Ser Asp Asp Leu Phe Tyr Gly Tyr Tyr His Asp Thr Asn 
165 170 175 
Gly Lys Asn Leu Val Asp Ala Ala Asp Lys Phe Ser Gln Tyr Phe Val 
180 185 190 
Val Tyr Asp Glu Lys Arg Val Asn Asp Asn Ile Ser Asp Lys Leu Thr 
195 200 205 
Ala Thr Tyr Arg Lys Lys Glu Gly Phe Val Tyr Gly Ser Asn Pro His 
210 215 220 
Thr Lys Glu Phe Ala Ala Arg Ile Ser Lys Leu Gly Asp Val Glu Ile 
225 230 235 240 
Lys Phe Glu Asn Gly Gln Ala Gln Gly Ser Ile Lys Asp Glu Lys Asp 
245 250 255 
Gly Asn Ala Glu Ile Phe Thr Ile Lys Gly Asp Thr Lys Gln Leu Glu 
260 265 270 
Ile Thr Pro Thr Glu Ser Asn Arg Ile Ile Ile Ala Ile Leu Asp Gln 
275 280 285 
Asn Gln Lys Ser Tyr Thr Pro Gly Met Glu Lys Ala Ile Met Glu Thr 
290 295 300 
20 
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-continued 
Lys Phe Ile Asp Ser Lys Ala Gly Asn Ser Asp Gln Lys Tyr Leu Ile 
305 310 315 320 
Gly Glu Ala Lys Ser Asp Asn Trp Gln Ala Ile Met Val Ser Glu Lys 
325 330 335 
Lys 
<210> SEQ ID NO 3 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 3 
cttggatccc aagcacaaaa tgtt 
<210> SEQ ID NO 4 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 4 
cctggatccc aagcagaggt tact 
<210> SEQ ID NO 5 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 5 
attggatcca atgctgaaca actc 
<210> SEQ ID NO 6 
<211> LENGTH: 33 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 6 
gactgaattc ttattttttc tcgctaacca tta 
<210> SEQ ID NO 7 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 7 
gataagcttt taccgtgcgg caaattc 
<210> SEQ ID NO 8 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 8 
aaaaagcttt tatttaattt ctacatc 
22 
24 
24 
24 
33 
27 
27 
<210> SEQ ID NO 9 
<211> LENGTH: 27 
<212> TYPE: DNA 
23 
<213> ORGANISM: Artificial 
<220> FEATURE: 
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<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 9 
tttaagcttt tatatacttc cttgagc 
<210> SEQ ID NO 10 
<211> LENGTH: 28 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 10 
gtcaggatcc tgcggaggaa gcggtagc 
<210> SEQ ID NO 11 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE: 11 
Pro Asn His Pro Lys Pro Val Leu Val Pro Lys Thr Gln Asn Asn Leu 
5 10 15 
<210> SEQ ID NO 12 
<211> LENGTH: 43 
<212> TYPE: PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE: 12 
Gln Asn Ala Ser Gln Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro 
1 5 10 15 
Gln Ala Gln Asn Ala Pro Gln Val Glu Asn Ala Pro Gln Ala Gln Asn 
20 25 30 
Ala Pro Gln Val Glu Asn Ala Pro Gln Ala Glu 
35 40 
<210> SEQ ID NO 13 
<211> LENGTH: 13 
<212> TYPE: PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE: 13 
Gly Ser Phe Asp Lys Ile Gly Ser Val Lys Leu Asn Lys 
1 5 10 
<210> SEQ ID NO 14 
<211> LENGTH: 19 
<212> TYPE: PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE: 14 
Lys Leu Gly Thr Pro Pro Lys Phe Asp Lys Val Ser Gly Lys Lys Ile 
1 5 10 15 
Ile Glu Glu 
<210> SEQ ID NO 15 
24 
27 
28 
US 7,144,580 B2 
25 26 
-continued 
<211> LENGTH: 13 
<212> TYPE: PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE: 15 
Leu Ile Arg Arg Ser Asp Asp Leu Phe Tyr Gly Tyr Tyr 
5 10 
<210> SEQ ID NO 16 
<211> LENGTH: 13 
<212> TYPE: PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE: 16 
Ala Asp Lys Phe Ser Gln Tyr Phe Val Val Tyr Asp Glu 
1 5 10 
<210> SEQ ID NO 17 
<211> LENGTH: 13 
<212> TYPE: PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE: 17 
Asn Ile Ser Asp Lys Leu Thr Ala Thr Tyr Arg Lys Lys 
5 10 
<210> SEQ ID NO 18 
<211> LENGTH: 13 
<212> TYPE: PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE: 18 
Pro His Thr Lys Glu Phe Ala Ala Arg Ile Ser Lys Leu 
5 10 
What is claimed is: 
1. A method of inducing a protective immune response in 
an at-risk bovine animal against infection caused by Man-
nheimia haemolytica comprising administering to said 
bovine animal a vaccine composition comprising between 
10 to about 100 micrograms of a purified recombinant PlpE 
outer membrane protein of Mannheimia haemolytica in a 
commercial adjuvant, wherein said purified recombinant 
PlpE comprises the amino acid sequence of SEQ ID NO: 2. 
2. The method of claim 1, wherein the vaccine composi-
40 tion further comprises at least one other antigen of Man-
nheimia haemolytica. 
3. The method of claim 1, wherein the vaccine composi-
tion comprises about 100 micrograms of said recombinant 
45 PlpE outer membrane protein. 
* * * * * 
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